XML 31 R21.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders | 9 Months Ended
--- | ---
Sep. 30, 2022
Earnings Per Share [Abstract] |
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders | 14. Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders The following table sets forth the computation of the basic and diluted net loss per share attributable to our common shareholders for the three and nine months ended September 30, 2022 and 2021, respectively (in thousands, except share and per share amounts):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Net loss attributable to Adaptive Biotechnologies Corporation |  | $ | (45,281 | ) |  | $ | (55,903 | ) |  | $ | (160,063 | ) |  | $ | (145,846 | )
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted |  |  | 142,928,654 |  |  |  | 140,833,564 |  |  |  | 142,334,342 |  |  |  | 140,060,379 |
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted |  | $ | (0.32 | ) |  | $ | (0.40 | ) |  | $ | (1.12 | ) |  | $ | (1.04 | )
Given the loss position for all periods presented, basic net loss per share attributable to our common shareholders is the same as diluted net loss per share attributable to our common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the three and nine months ended September 30, 2022 and 2021, respectively, as they had an anti-dilutive effect:
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Stock options outstanding |  |  | 13,996,403 |  |  |  | 12,901,028 |  |  |  | 13,984,427 |  |  |  | 13,205,328 |
Nonvested restricted stock units outstanding |  |  | 5,486,711 |  |  |  | 795,469 |  |  |  | 4,490,170 |  |  |  | 572,194 |
Maximum nonvested market-based restricted stock units outstanding eligible to be earned |  |  | 494,234 |  |  |  | — |  |  |  | 381,990 |  |  |  | — |
Common stock warrant outstanding |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 11,458 |
Total |  |  | 19,977,348 |  |  |  | 13,696,497 |  |  |  | 18,856,587 |  |  |  | 13,788,980 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI https://asc.fasb.org/topic&trid=2144383 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration